JP2023088944A5 - - Google Patents

Download PDF

Info

Publication number
JP2023088944A5
JP2023088944A5 JP2023040600A JP2023040600A JP2023088944A5 JP 2023088944 A5 JP2023088944 A5 JP 2023088944A5 JP 2023040600 A JP2023040600 A JP 2023040600A JP 2023040600 A JP2023040600 A JP 2023040600A JP 2023088944 A5 JP2023088944 A5 JP 2023088944A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
csa
dose
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023040600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023088944A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/040181 external-priority patent/WO2019006235A1/en
Application filed filed Critical
Publication of JP2023088944A publication Critical patent/JP2023088944A/ja
Publication of JP2023088944A5 publication Critical patent/JP2023088944A5/ja
Priority to JP2025121073A priority Critical patent/JP2025165979A/ja
Pending legal-status Critical Current

Links

JP2023040600A 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法 Pending JP2023088944A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025121073A JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
JP2019570045A JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019570045A Division JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025121073A Division JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Publications (2)

Publication Number Publication Date
JP2023088944A JP2023088944A (ja) 2023-06-27
JP2023088944A5 true JP2023088944A5 (enExample) 2023-09-01

Family

ID=63013097

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019570045A Pending JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019570045A Pending JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Country Status (22)

Country Link
US (4) US11576910B2 (enExample)
EP (2) EP4512470A3 (enExample)
JP (3) JP2020526483A (enExample)
CN (1) CN110996953A (enExample)
AU (2) AU2018290983B2 (enExample)
BR (1) BR112019028046A2 (enExample)
CA (1) CA3068588A1 (enExample)
DK (1) DK3645002T3 (enExample)
ES (1) ES3008457T3 (enExample)
FI (1) FI3645002T3 (enExample)
HR (1) HRP20241729T1 (enExample)
HU (1) HUE069805T2 (enExample)
LT (1) LT3645002T (enExample)
MA (1) MA49508B1 (enExample)
MD (1) MD3645002T2 (enExample)
MX (2) MX2020000190A (enExample)
PL (1) PL3645002T3 (enExample)
PT (1) PT3645002T (enExample)
RS (1) RS66581B1 (enExample)
SI (1) SI3645002T1 (enExample)
SM (1) SMT202500067T1 (enExample)
WO (1) WO2019006235A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008789A0 (en) 2013-03-14 2015-10-31 Cytokinetics Inc Heterocyclic compounds and their uses
CN110996953A (zh) 2017-06-30 2020-04-10 安进公司 用心脏肌小节激活剂治疗心力衰竭的方法
MD3645518T2 (ro) 2017-06-30 2021-11-30 Amgen Inc Sinteză de mercabil omecamtiv
LT3594199T (lt) 2018-07-09 2020-11-10 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas
CA3108800A1 (en) 2018-08-17 2020-02-20 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
CN114173782A (zh) * 2019-05-19 2022-03-11 迈奥卡迪亚公司 利用化合物(r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺治疗心缩功能障碍和具有减小的射血分数的心脏衰竭
CN115279349A (zh) * 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
AU2021293817A1 (en) * 2020-06-15 2023-01-19 MyoKardia, Inc. Treatment of atrial dysfunction
EP4243825B1 (en) 2020-11-12 2025-11-12 Amgen Inc. Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
WO2022192414A2 (en) 2021-03-10 2022-09-15 Amgen Inc. Synthesis of omecamtiv mecarbil
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
CN1296417A (zh) 1998-02-10 2001-05-23 卫福有限公司 控释制剂
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
WO2006009726A2 (en) 2004-06-17 2006-01-26 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
MX2008014418A (es) 2006-05-15 2008-11-27 Wisconsin Alumni Res Found Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
AP2015008789A0 (en) 2013-03-14 2015-10-31 Cytokinetics Inc Heterocyclic compounds and their uses
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
CN110603049A (zh) 2017-02-06 2019-12-20 阿塞勒隆制药公司 用于治疗心力衰竭的组合物和方法
CN110996953A (zh) 2017-06-30 2020-04-10 安进公司 用心脏肌小节激活剂治疗心力衰竭的方法
MD3645518T2 (ro) 2017-06-30 2021-11-30 Amgen Inc Sinteză de mercabil omecamtiv
LT3594199T (lt) 2018-07-09 2020-11-10 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
FI3599243T3 (fi) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon
CA3108800A1 (en) 2018-08-17 2020-02-20 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
CA3130261A1 (en) 2019-03-05 2020-09-10 Windtree Therapeutics, Inc. Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
EP4045492A1 (en) 2019-09-19 2022-08-24 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
US20230158027A1 (en) 2019-11-10 2023-05-25 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CN115279349A (zh) 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
EP4243825B1 (en) 2020-11-12 2025-11-12 Amgen Inc. Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
WO2022192414A2 (en) 2021-03-10 2022-09-15 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Similar Documents

Publication Publication Date Title
JP2023088944A5 (enExample)
KR101718639B1 (ko) 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생
FI3645002T3 (fi) Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla
US3795739A (en) Treatment of parkinson disease
JP2020526483A5 (enExample)
JP2020529996A5 (enExample)
JP2007506752A (ja) 肺動脈高血圧症を治療するための併用療法におけるイロプロスト
WO2007149283B1 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
Mooss et al. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2020529440A5 (enExample)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
JP2024178420A5 (enExample)
CN104039148A (zh) 组合als疗法
EP2988750B1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
JP3084059B2 (ja) 甲状腺ホルモン心臓治療
JP2011518147A (ja) 血中カリウム濃度を調節する薬剤を調製するためのドロネダロンまたは医薬的に許容されるこの塩の使用
JP2012525358A5 (enExample)
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
JP2019535830A5 (enExample)
JP2019178177A5 (enExample)
JPWO2019236757A5 (enExample)
JPWO2023049920A5 (enExample)
JP2018177773A (ja) 医薬